» Articles » PMID: 9193357

Incidence, Predictive Factors, and Outcome of Lymphoma Transformation in Follicular Lymphoma Patients

Overview
Journal J Clin Oncol
Specialty Oncology
Date 1997 Apr 1
PMID 9193357
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To assess the incidence of lymphoma transformation in the natural history of follicular lymphoma (FL) patients and the factors that are predictive of this event.

Patients And Methods: Two hundred twenty patients with FL treated in our institution between 1975 and 1990, with a median follow-up duration of 9 years, were included in this retrospective analysis.

Results: Transformation was proven by histology in 34 patients or by cytology in 13 patients and was considered as highly probable on clinical arguments in five patients for an overall incidence of 24%. The probability of transformation was 22% at 5 years and 31% at 10 years and tended to plateau after 6 years. Predictive factors for transformation were nonachievement of complete remission (CR) after initial therapy (P < 10(-4), low serum albumin level (< 35 g/L) (P = .001), and beta 2-microglobulin level greater than 3 mg/L (P = .02) at diagnosis. In a multiparametric analysis, only beta 2-microglobulin level retained prognostic significance for freedom-from-transformation (FFT) survival (P = .04). Transformation accounted for 44% of deaths and was associated with a poor outcome, with a median survival time of 7 months.

Conclusion: Transformation is an early event in the course of the disease and is mainly observed in patients with known adverse prognostic factors or those who do not achieve CR after initial treatment. These findings may be useful to select follicular lymphoma patients for intensive therapeutic approaches.

Citing Articles

Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation.

Kubo R, Onodera K, Onishi Y, Fukuhara N, Harigae H Ann Hematol. 2024; 104(1):841-845.

PMID: 39738826 DOI: 10.1007/s00277-024-06150-8.


Clinical-Demographic Profile, Prognostic Factors and Outcomes in Classic Follicular Lymphoma Stratified by Staging and Tumor Burden: Real-World Evidence from a Large Latin American Cohort.

Nogueira D, Lage L, Reichert C, Culler H, de Freitas F, Mendes J Cancers (Basel). 2024; 16(23).

PMID: 39682103 PMC: 11640734. DOI: 10.3390/cancers16233914.


Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies.

Olejarz W, Sadowski K, Szulczyk D, Basak G Int J Mol Sci. 2024; 25(14).

PMID: 39062986 PMC: 11276786. DOI: 10.3390/ijms25147743.


Risk of transformation by frontline management in follicular and marginal zone lymphomas: a US population-based analysis.

Florindez J, Chihara D, Reis I, Lossos I, Alderuccio J Blood Adv. 2024; 8(16):4423-4432.

PMID: 38954843 PMC: 11375286. DOI: 10.1182/bloodadvances.2024013499.


Outcomes of the transformation of follicular lymphoma to diffuse large B-cell lymphoma in the rituximab era: A population-based study.

Zheng W, Liu M, Guan L, Wang S Cancer Med. 2024; 13(8):e7120.

PMID: 38629251 PMC: 11022146. DOI: 10.1002/cam4.7120.